Arcturus Therapeutics Analyst Price Targets - Benzinga

Arcturus Therapeutics Holdings Inc

ARCTNASDAQ

Trade with Public

Trade with Public

$13.15

-1.51-10.3%

Últ. Act.: Oct 6, 3:44 PM

$14.70

0.040.27%

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Comparar Opciones Informe de acciones

Arcturus Therapeutics Analyst Price Targets - Benzinga

Arcturus Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Arcturus Therapeutics (ARCT).

Price Target Range — 11 Quarters

Analyst Consensus — 11 Analysts

9Buy

2Hold

Consensus RatingBuy# Analysts11Avg. Consensus PT$34Upside to Avg. PT+156.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 24, 2026	Citigroup	Yigal Nochomovitz	Upgrade	Neutral→Buy	$8→$20
Sep 24, 2026	BTIG	Thomas Shrader	PT Cut	Buy	$23→$20
Jul 2, 2026	Freedom Broker	Ilya Zubkov	Initiate	Buy	$27
Mar 18, 2026	B. Riley Securities	Mayank Mamtani	Initiate	Neutral→Buy	$22
Mar 5, 2026	Citigroup	Whitney Ijem	PT Cut	Buy	$66→$21
Mar 4, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Neutral	$7→$8
Mar 4, 2026	Piper Sandler	Yasmeen Rahimi	PT Cut	Overweight	$72→$25
Jan 6, 2026	Citigroup	Yigal Nochomovitz	PT Cut	Neutral	$9→$7
Nov 13, 2025	Citigroup	Yigal Nochomovitz	PT Cut	Neutral	$12→$9
Nov 11, 2025	Piper Sandler	Yasmeen Rahimi	PT Cut	Overweight	$140→$72
Nov 11, 2025	HC Wainwright & Co.	Andrew S. Fein	PT Cut	Neutral	$12→$9
Oct 24, 2025	HC Wainwright & Co.	Andrew S. Fein	Downgrade	Buy→Neutral	$60→$12
Oct 23, 2025	Citigroup	Yigal Nochomovitz	Downgrade	Buy→Neutral	$49→$12
Oct 23, 2025	Wells Fargo	Yanan Zhu	PT Cut	Overweight	$42→$20
Oct 23, 2025	Guggenheim	Seamus Fernandez	Downgrade	Buy→Neutral	—
Oct 22, 2025	BTIG	Thomas Shrader	PT Cut	Buy	$48→$23
Oct 22, 2025	Guggenheim	Seamus Fernandez	Downgrade	Buy→Neutral	—
Sep 4, 2025	HC Wainwright & Co.	Andrew S. Fein	Assumes	Buy	$60
Aug 22, 2025	Leerink Partners	Lili Nsongo	PT Cut	Outperform	$63→$54
Aug 12, 2025	Wells Fargo	Yanan Zhu	PT Cut	Overweight	$45→$42

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Citigroup Upgrades Arcturus Therapeutics to Buy, Raises Price Target to $20

Citigroup analyst Yigal Nochomovitz upgrades Arcturus Therapeutics (NASDAQ:ARCT) from Neutral to Buy and raises the price target from $8 to $20.

Benzinga Newsdesk

PRO
BTIG Maintains Buy on Arcturus Therapeutics, Lowers Price Target to $20

BTIG analyst Thomas Shrader maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and lowers the price target from $23 to $20.

Benzinga Newsdesk

This Adobe Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday

Top analysts upgraded Palantir, Silicom, Adobe, and Chevron. See what other analysts think about these stocks. Photo via Shutterstock.

Avi Kapoor

This Honeywell Aerospace Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Wall Street analysts change outlook on top names. Check analyst ratings page for all changes. Consider buying HONA stock - analysts' thoughts.

Avi Kapoor

PRO
Freedom Broker Initiates Coverage On Arcturus Therapeutics with Buy Rating, Announces Price Target of $27

Freedom Broker analyst Ilya Zubkov initiates coverage on Arcturus Therapeutics (NASDAQ:ARCT) with a Buy rating and announces Price Target of $27.

Benzinga Newsdesk

This Rubrik Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday

Wall Street analysts changed ratings on top stocks. For insights on changes, see analyst ratings page. RBRK stock: buy or not? Analysts weigh in.

Avi Kapoor